Holen Sie sich die Stockscreener-App
3.82
1.29%
-0.05
Schlusskurs vom Vortag:
$3.87
Offen:
$3.83
24-Stunden-Volumen:
789.78K
Relative Volume:
1.51
Marktkapitalisierung:
$268.45M
Einnahmen:
$114.70K
Nettoeinkommen (Verlust:
$-12.82M
KGV:
-1.4288
EPS:
-2.6735
Netto-Cashflow:
$-45.71M
1W Leistung:
+3.24%
1M Leistung:
-2.80%
6M Leistung:
+81.90%
1J Leistung:
+135.80%
1-Tages-Spanne:
$3.78
$3.94
1-Wochen-Bereich:
$3.69
$3.99
52-Wochen-Spanne:
$1.00
$6.60
Sab Biotherapeutics Inc Stock (SABS) Company Profile
Firmenname
Sab Biotherapeutics Inc
Sektor
Branche
Telefon
305-845-2813
Adresse
777 W 41ST ST, MIAMI BEACH
Compare SABS vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
3.82 | 268.45M | 114.70K | -12.82M | -45.71M | -2.6735 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-19 | Eingeleitet | Guggenheim | Buy |
| 2025-09-17 | Eingeleitet | Leerink Partners | Outperform |
| 2025-05-14 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-10-09 | Eingeleitet | Craig Hallum | Buy |
| 2024-08-28 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Sab Biotherapeutics Inc Aktie (SABS) Neueste Nachrichten
SAB Biotherapeutics (SABS) CMO has common shares withheld for taxes - Stock Titan
SAB Biotherapeutics - Global Legal Chronicle
[SCHEDULE 13D/A] SAB B... - Stock Titan
SAB Biotherapeutics Completes $85 Million Public Offering - Global Legal Chronicle
SAB Biotherapeutics closes $85 million public offering - The Pharma Letter
SAB Biotherapeutics (SABS) to Release Earnings on Friday - MarketBeat
SAB Biotherapeutics announces public stock offering; shares down - MSN
SAB Biotherapeutics Closes $85 Million Securities Offering - marketscreener.com
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants - Weekly Voice
SAB BIO raises $85 million to fund diabetes drug trials - Stock Titan
SAB Biotherapeutics (SABS) raises $69.7M net to advance SAB‑142 clinical program - Stock Titan
SAB Biotherapeutics Launches Major Equity Financing Offering - TipRanks
SAB Biotherapeutics (NASDAQ: SABS) to raise $85M for SAB-142 trials - Stock Titan
SAB Biotherapeutics Prices Underwritten Equity Offering; About $69.7 Million Net Proceeds Expected - TradingView
Stock Recap: Is SAB Biotherapeutics Inc being accumulated by smart money2026 Market Outlook & Low Volatility Stock Recommendations - baoquankhu1.vn
Guggenheim initiates coverage of SAB Biotherapeutics (SABS) with buy recommendation - MSN
SAB Biotherapeutics prices $85M stock offering at $3.85/share By Investing.com - Investing.com South Africa
SAB Biotherapeutics prices $85M stock offering at $3.85/share - Investing.com
Sab Bio announces pricing of $85 million public offering of common stock at $3.85 per share - marketscreener.com
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
SAB Biotherapeutics, Inc. Prices Public Offering of Common Stock and Pre-Funded Warrants to Raise Approximately $85 Million - Quiver Quantitative
SAB BIO plans $85M funding push for experimental type 1 diabetes treatment - Stock Titan
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants - Benzinga
SAB Biotherapeutics (SABS) to offer common stock and pre-funded warrants - Stock Titan
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Biotech SAB BIO plans stock sale to fund Type 1 diabetes trials - Stock Titan
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Update - MarketBeat
Commodore Capital LP Takes Position in SAB Biotherapeutics, Inc. $SABS - MarketBeat
SAB Biotherapeutics (NASDAQ:SABS) Cut to “Strong Sell” at Zacks Research - Defense World
SAB Biotherapeutics reports early C-peptide signals in phase 1 trial - Investing.com Nigeria
SAB Biotherapeutics (NASDAQ:SABS) Downgraded to Strong Sell Rating by Zacks Research - MarketBeat
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
SAB Biotherapeutics (NASDAQ:SABS) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Analysts Offer Insights on Healthcare Companies: Rapport Therapeutics, Inc. (RAPP), SAB Biotherapeutics (SABS) and Encompass Health (EHC) - The Globe and Mail
SAB Biotherapeutics (NASDAQ:SABS) Stock Price Expected to Rise, Chardan Capital Analyst Says - Defense World
Chardan Capital Raises SAB Biotherapeutics Price Target to $14 - National Today
Chardan Capital Raises SAB Biotherapeutics (NASDAQ:SABS) Price Target to $14.00 - MarketBeat
H.C. Wainwright cuts SAB Biotherapeutics price target to $7 on dilution - Investing.com
SAB Biotherapeutics (NASDAQ:SABS) Given New $7.00 Price Target at HC Wainwright - Defense World
SAB Biotherapeutics Announces Positive Phase 1 Results for SAB-142 Showing C-Peptide Preservation in Adult Type 1 Diabetes Patients - Minichart
SAB Biotherapeutics, Inc. 2024 Annual Report: Business Overview, Pipeline, and Strategic Outlook - Minichart
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes - National Today
SAB Biotherapeutics (NASDAQ:SABS) Price Target Cut to $7.00 by Analysts at HC Wainwright - MarketBeat
SAB Biotherapeutics Highlights New Phase 1 SAB-142 Data - TipRanks
SAB Bio (SAB Biotherapeutics, Inc.) recently released further data from a Phase I clinical trial of its candidate drug SAB-142 in adult patients diagnosed with autoimmune type 1 diabetes. - Bitget
SAB Bio reports Phase 1 SAB-142 data showing C-peptide preservation signals in adult T1D cohort - TradingView
Phase 1 SAB-142 data from SAB BIO (Nasdaq: SABS) highlight early T1D signal - Stock Titan
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights - Investing News Network
SAB BIO backs diabetes therapy with $175M and 2027 trial goal - Stock Titan
SAB Biotherapeutics 10-K: Revenue $0, Net income $13.27M - TradingView
SAB Biotherapeutics (SABS) boosts cash with $175M raise and 2025 warrant gain - Stock Titan
Finanzdaten der Sab Biotherapeutics Inc-Aktie (SABS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):